Journal of Affective Disorders
Volume 82, Issue 3 , Pages 453-459 , 1 November 2004

Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants

  • Orli Kampf-Sherf

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +972-52-710836; fax: +972-2-5813288.
    • Department of Psychology, Hebrew University, POB 24288, Jerusalem 91242, Israel
    • ,
  • Zoli Zlotogorski

      Affiliations

    • Hebrew University of Jerusalem, Jerusalem, Israel
    • ,
  • Asaf Gilboa

      Affiliations

    • Department of Psychology, Hebrew University, POB 24288, Jerusalem 91242, Israel
    • ,
  • Lynn Speedie

      Affiliations

    • Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    • ,
  • Jossef Lereya

      Affiliations

    • Shalvata Psychiatric Health Center, Hod Hasharon, Israel
    • ,
  • Paula Rosca

      Affiliations

    • Winnick Clinic, Talbieh Mental Health Center, Jerusalem, Israel
    • ,
  • Yehuda Shavit

      Affiliations

    • Department of Psychology, Hebrew University, POB 24288, Jerusalem 91242, Israel

Received 22 April 2003 ,Revised 27 February 2004 ,Accepted 27 February 2004.

References 

  1. Ainslie G. Specious reward: a behavioural theory of impulsiveness and impulse control. Psychol. Bull. 1975;82:463–469
  2. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: A biochemical suicide predictor?. Arch. Gen. Psychiatry. 1976;33:1193–1197
  3. Beck AT. Cognitive therapy: a 30-year retrospective. Am. Psychol. 1991;46:368–375
  4. Benton AL. A Visual Retention Test for Clinical Use. New York, NY: Psychological; 1946;
  5. Benton AL. Revised Visual Retention Test. New York, NY: The Psychological; 1974;
  6. Bizot JC, Thiebot MH. Impulsivity as a confounding factor in certain animal tests of cognitive function. Cogn. Brain Res. 1996;3:243–250
  7. Bruder GE, Stewart JW, Voglmaier MM, Harrison WM, McGarth P, Tricamo E, et al. Cerebral laterality and depression: relations of perceptual asymmetry to outcome of treatment with tricyclic antidepressants. Neuropsychopharmacology. 1990;3:1–10
  8. Carson AJ, MacHale S, Allen K, Lawrie SM, Dennis M, House A, et al. Depression after stroke and lesion location: a systematic review. Lancet. 2000;356(9224):122–126
  9. Conti L, Dell'Osso L, Re F, Musetti L, Cassano GB. Fluvoxamine melate: double-blind clinical trial vs. placebo in hospitalized depressed patients. Curr. Ther. Res. 1988;43:480–648
  10. Cutting J. In: The Right Cerebral Hemisphere and Psychiatric Disorders. New York, NY: Oxford Univ. Press; 1990;p. 357–367
  11. D'Esposito M, Aguirre GK, Zarahn E, Ballard D, Shin RK, Lease J. Functional MRI studies of spatial and nonspatial working memory. Cogn. Brain Res. 1998;7:1–13
  12. De Wilde JE, Mertens C, Wakelin JS. Clinical trials of fluvoxamine vs. chlorimipramine with single and three times daily dosing. Br. J. Clin. Pharmacol. 1983;15:427S–431S
  13. Dick P, Ferrero E. A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine. Br. J. Clin. Pharmacol. 1983;15:419S–425S
  14. Fava M, Vuolo RD, Wright EC, Nierenberg AA, Alpert JE, Rosenbaum JF. Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Res. 2000;94:9–18
  15. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for Axis I DSM-IV Disorders. Patient edition. New York, NY: Biometrics Research Dept., New York State Psychiatric Institute; 1994; SCID I/P, version 2.0
  16. Flor-Henry P. Lateralized temporal limbic dysfunctions and psychopathology. Ann. N.Y. Acad. Sci. 1976;280:777–795
  17. Goodman WK, Price LHP, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive–compulsive disorder. Arch. Gen. Psychiatry. 1989;46:38–44
  18. Guelfi JD, Dreyfus JF, Pichot P  the GEPECEP . Fluvoxamine and imipramine: results of a long-term controlled trial. Int. Clin. Psychopharmacol. 1987;2:103–109
  19. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1967;6:278–296
  20. Harvey JA. Serotonergic regulation of associative learning. Behav. Brain Res. 1996;73:47–50
  21. Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol. Psychiatry. 1993;33:173–187
  22. Hooper HE. Hooper Visual Organization Test (VOT). Los Angeles, CA: Western Psychological Services; 1983;
  23. Jakala P, Sirvio J, Riekkinen P, Riekkinen PJ. Effects of p-chlorophenylalanine and methisergide on the performance of a working memory task. Pharmacol. Biochem. Behav. 1993;44:411–418
  24. Lee GP, Loring DW, Meador KJ, Brooks BB. Hemispheric specialization for emotional expression: a reexamination of results from intracarotid administration of sodium amobarbital. Brain Cognition. 1990;12:267–280
  25. Lezak, M.D., 1995. Neuropsychological Assessment. Oxford University Press, New York, NY. pp. 66–69, 409–411, 438–444, 475–479, 544–548, 569–579, 587–594, 605–606, 641–644.
  26. Lopez-Ibor JJ. The involvement of serotonin in psychiatric disorders and behaviour. British Journal of Psychiatry. 1988;153:26–39
  27. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiat. Scand. 1998;97:302–308
  28. Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide—a review of postmortem studies. Br. J. Psychiatry. 1989;155(Suppl. 8):7–14
  29. Martin AJ, Tebbs VM, Ashford JJ. Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. Pharmatherapeutica. 1987;5:40–49
  30. McCann UD, Mertl M, Eligulashvili V, Ricuarte GA. Cognitive performance in (+/−) 3,4-methylenediaxymethamphetamine (MDMA, “ecstasy”) users: a controlled study. Psychopharmacology. 1999;143:417–425
  31. Osterrieth PA. Le test de copie d'une figure complex: contribution a l'etude de la perception et de la memoire. Arch. Psychol. 1944;30:286–356
  32. Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW, et al. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology. 1994;33:575–588
  33. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Arch. Psychol. 1941;28:286–340
  34. Rey A. L'examen clinique en psychologie. Paris, France: Presses Universitaires de France; 1964;
  35. Riedel WJ, Klaassen T, Deutz NE, van-Someren A, van-Praag HM. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology. 1999;141:362–369
  36. Robert PH, Aubin-Brubet V, Darcourt G. Serotonin and the frontal lobes. In:  Miller BL,  Cummings JL editor. The Human Frontal Lobes. New York, NY: The Guilford Press; 1999;p. 130
  37. Shalev AY, Abramowitz MZ, Kaplan-De-Nour A. Structured Clinical Interview for Axis I DSM-IV Disorders. Patient edition. Jerusalem, Israel: Center for Traumatic Stress, Dept. of Psychiatry, Hadassah University Hospital; 1994; SCID I/P, version 2.0 May 94, Hebrew Version
  38. Smith ML, Milner B. Estimation of frequency of occurrence of abstract designs after frontal or temporal lobectomy. Neuropsychologia. 1988;26:297–306
  39. Stanley M, Stanley B. Postmortem evidence for serotonin's role in suicide. J. Clin. Psychiatry. 1990;51(Suppl. 4):22–28
  40. Stokes PE. Rationale for antidepressant selection. In: Proc. 8th Int. Psychiat. Forum. vol. 1:1992;p. 5–9
  41. Stokes PE. Fluoxetine: a five-year review. Clin. Ther. 1993;15:216–243
  42. Taylor EM. Psychological Appraisal of Children with Cerebral Defects. Cambridge, MA: Harvard Univ. Press; 1959;
  43. Tenen SS. The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance acquisition, pain sensitivity and related behavior in the rat. Psychopharmacology. 1967;10:204–219
  44. Thase ME, Rush AJ. Treatment-resistant depression. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: The Fourth Generation of Progress. NY: Raven Press; 1995;
  45. Thiebot MH, LeBihan C, Soubrie P, Simon P. Benzodiazepines reduce the tolerance to reward delay in rats. Psychopharmacology. 1985;86:147–152
  46. Tiffin J, Asher EJ. The Purdue Pegboard: norms and studies of reliability and validity. J. Appl. Psychol. 1948;32:234–247
  47. Turner P. Dexfenfluramine: its place in weight control. Drugs. 1990;39(Suppl. 3):53–62
  48. Twain DC. Factor analysis of a particular aspect of behavioral control: impulsivity. J. Clin. Psychol. 1957;13:133–136
  49. Vakil E, Blachstein H. Rey AVLT: developmental norms for adults and the sensitivity of different memory measures to age. Clin. Neuropsychol. 1997;11:356–369
  50. Wagner AD. Working memory contributions to human learning and remembering. Neuron. 1999;22:19–22
  51. Wechsler D. WAIS Manual. New York, NY: The Psychological; 1955;
  52. Wechsler D. WAIS–R Manual. New York, NY: The Psychological; 1981;
  53. Weingartner H, Cohen RM, Murphy DL, Martello J, Gerdt C. Cognitive processes in depression. Arch. Gen. Psychiatry. 1981;38:42–47

PII: S0165-0327(04)00088-6

doi: 10.1016/j.jad.2004.02.006

Journal of Affective Disorders
Volume 82, Issue 3 , Pages 453-459 , 1 November 2004

Article Tools

* Image Usage & Resolution